A safe and effective drug with a six-month (or longer) dosing interval in wet-amd and open-angle glaucoma would be a major advance in patient convenience and satisfaction. The business proposition is similar to what RVNC is doing with Daxi.
*Assuming exercise of underwriter’s option.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.